Yüksel Akkaya, Begüm Nalça Erdin, Ahmet Münir Yılmaz, İbrahim Halil Kılıç, Zülal Aşçı Toraman
{"title":"土耳其伊斯坦布尔某三级医院耳念珠菌鉴定及抗真菌耐药性分析。","authors":"Yüksel Akkaya, Begüm Nalça Erdin, Ahmet Münir Yılmaz, İbrahim Halil Kılıç, Zülal Aşçı Toraman","doi":"10.5144/0256-4947.2025.207","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Candida (Candidozyma) auris</i> is a high priority fungal pathogen due to its antifungal resistance and its association with increased morbidity and mortality in infected patients.</p><p><strong>Objectives: </strong>The aim of this study was to identify Candida species in clinical samples and to determine the clades and in vitro antifungal resistance of <i>C. auris</i>.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Settings: </strong>Single-center tertiary hospital in Türkiye.</p><p><strong>Material and methods: </strong>The study was conducted in the Medical Microbiology Laboratory of Ümraniye Training and Research Hospital between December 2023 and October 2024. Fungal samples were identified using bio-Mérieux VITEK MS v.3.2 (bio-Mérieux, France) and RT-PCR. Antifungal susceptibility testing of <i>C. auris</i> was performed by VITEK 2 Compact AST YS08 and SYO.</p><p><strong>Main outcome measures: </strong>Identification of Candida species, in-vitro antifungal resistance of <i>C. auris</i>.</p><p><strong>Sample size: </strong>846 fungal isolates obtained from 746 patients were included.</p><p><strong>Results: </strong>A total of 846 fungal isolates were identified, with <i>C. albicans</i> being the most common (n=440, 52%), followed by <i>Nakaseomyces glabratus</i> (n=124, 14.7%), <i>C. parapsilosis</i> (n=85, 10.1%), <i>C. tropicalis</i> (n=69, 8.2%) and <i>C. auris</i> (n=57, 6.7%). All <i>C. auris</i> isolates were susceptible to anidulafungin. Of these isolates, 47 (82%) were resistant to fluconazole, 34 (60%) to amphotericin B, four (7%) to caspofungin and three (5%) to micafungin. One isolate was resistant to amphotericin B, fluconazole, caspofungin and micafungin. A total of 31 (54%) isolates were resistant to amphotericin B and fluconazole. In accordance with the manufacturer's recommendations, 57 isolates were evaluated as Clade-1.</p><p><strong>Conclusion: </strong><i>C. auris</i> infections are becoming increasingly common. In order to better understand antifungal-resistance of this pathogen, advanced methods should be used for rapid detection of clades and mutations in the FKS gene should be revealed.</p><p><strong>Limitations: </strong>Single center, whole genome sequence analysis were not performed.</p>","PeriodicalId":93875,"journal":{"name":"Annals of Saudi medicine","volume":"45 4","pages":"207-217"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318251/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification and antifungal resistance profiling of <i>Candida (Candidozyma) auris</i> in a tertiary hospital in Istanbul, Türkiye.\",\"authors\":\"Yüksel Akkaya, Begüm Nalça Erdin, Ahmet Münir Yılmaz, İbrahim Halil Kılıç, Zülal Aşçı Toraman\",\"doi\":\"10.5144/0256-4947.2025.207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong><i>Candida (Candidozyma) auris</i> is a high priority fungal pathogen due to its antifungal resistance and its association with increased morbidity and mortality in infected patients.</p><p><strong>Objectives: </strong>The aim of this study was to identify Candida species in clinical samples and to determine the clades and in vitro antifungal resistance of <i>C. auris</i>.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Settings: </strong>Single-center tertiary hospital in Türkiye.</p><p><strong>Material and methods: </strong>The study was conducted in the Medical Microbiology Laboratory of Ümraniye Training and Research Hospital between December 2023 and October 2024. Fungal samples were identified using bio-Mérieux VITEK MS v.3.2 (bio-Mérieux, France) and RT-PCR. Antifungal susceptibility testing of <i>C. auris</i> was performed by VITEK 2 Compact AST YS08 and SYO.</p><p><strong>Main outcome measures: </strong>Identification of Candida species, in-vitro antifungal resistance of <i>C. auris</i>.</p><p><strong>Sample size: </strong>846 fungal isolates obtained from 746 patients were included.</p><p><strong>Results: </strong>A total of 846 fungal isolates were identified, with <i>C. albicans</i> being the most common (n=440, 52%), followed by <i>Nakaseomyces glabratus</i> (n=124, 14.7%), <i>C. parapsilosis</i> (n=85, 10.1%), <i>C. tropicalis</i> (n=69, 8.2%) and <i>C. auris</i> (n=57, 6.7%). All <i>C. auris</i> isolates were susceptible to anidulafungin. Of these isolates, 47 (82%) were resistant to fluconazole, 34 (60%) to amphotericin B, four (7%) to caspofungin and three (5%) to micafungin. One isolate was resistant to amphotericin B, fluconazole, caspofungin and micafungin. A total of 31 (54%) isolates were resistant to amphotericin B and fluconazole. In accordance with the manufacturer's recommendations, 57 isolates were evaluated as Clade-1.</p><p><strong>Conclusion: </strong><i>C. auris</i> infections are becoming increasingly common. In order to better understand antifungal-resistance of this pathogen, advanced methods should be used for rapid detection of clades and mutations in the FKS gene should be revealed.</p><p><strong>Limitations: </strong>Single center, whole genome sequence analysis were not performed.</p>\",\"PeriodicalId\":93875,\"journal\":{\"name\":\"Annals of Saudi medicine\",\"volume\":\"45 4\",\"pages\":\"207-217\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318251/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Saudi medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5144/0256-4947.2025.207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5144/0256-4947.2025.207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Identification and antifungal resistance profiling of Candida (Candidozyma) auris in a tertiary hospital in Istanbul, Türkiye.
Background: Candida (Candidozyma) auris is a high priority fungal pathogen due to its antifungal resistance and its association with increased morbidity and mortality in infected patients.
Objectives: The aim of this study was to identify Candida species in clinical samples and to determine the clades and in vitro antifungal resistance of C. auris.
Design: Retrospective cohort.
Settings: Single-center tertiary hospital in Türkiye.
Material and methods: The study was conducted in the Medical Microbiology Laboratory of Ümraniye Training and Research Hospital between December 2023 and October 2024. Fungal samples were identified using bio-Mérieux VITEK MS v.3.2 (bio-Mérieux, France) and RT-PCR. Antifungal susceptibility testing of C. auris was performed by VITEK 2 Compact AST YS08 and SYO.
Main outcome measures: Identification of Candida species, in-vitro antifungal resistance of C. auris.
Sample size: 846 fungal isolates obtained from 746 patients were included.
Results: A total of 846 fungal isolates were identified, with C. albicans being the most common (n=440, 52%), followed by Nakaseomyces glabratus (n=124, 14.7%), C. parapsilosis (n=85, 10.1%), C. tropicalis (n=69, 8.2%) and C. auris (n=57, 6.7%). All C. auris isolates were susceptible to anidulafungin. Of these isolates, 47 (82%) were resistant to fluconazole, 34 (60%) to amphotericin B, four (7%) to caspofungin and three (5%) to micafungin. One isolate was resistant to amphotericin B, fluconazole, caspofungin and micafungin. A total of 31 (54%) isolates were resistant to amphotericin B and fluconazole. In accordance with the manufacturer's recommendations, 57 isolates were evaluated as Clade-1.
Conclusion: C. auris infections are becoming increasingly common. In order to better understand antifungal-resistance of this pathogen, advanced methods should be used for rapid detection of clades and mutations in the FKS gene should be revealed.
Limitations: Single center, whole genome sequence analysis were not performed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
